Business Context and Reporting Period
Company: Centene Corporation
Filing Type: Form 8-K (Current Report)
Date of Report: July 28, 2026
Reporting Period: Second quarter ended June 30, 2026 (financial results announced via press release).
Key Financial Metrics
This Form 8-K serves as a notification of the release of financial results for the second quarter ended June 30, 2026. The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained in the press release attached as Exhibit 99.1, which is incorporated by reference but not detailed within the body of this report.
Material Changes and Corporate Governance
The filing reports significant changes to the Board of Directors effective July 28, 2026:
- Resignation: Director Kenneth Burdick resigned from the Board and the Quality and Compliance Committee. The resignation was not the result of any dispute with the Company.
- Appointment: Paul Diaz was elected to the Board to fill the vacancy created by Mr. Burdick. His term expires at the 2027 annual meeting of stockholders.
- Committee Assignments: Mr. Diaz was appointed to the Audit Committee and the Quality and Compliance Committee.
- Background: Mr. Diaz is a Managing Partner at Cressey & Company (since May 2025) and formerly served as President and CEO of Myriad Genetics, Inc. (2020–2025) and Kindred Healthcare (2004–2015).
Guidance, Outlook, and Risks
The filing text does not contain specific guidance, outlook, management commentary, or risk factors regarding the financial results. It references a press release (Exhibit 99.1) for the financial announcement and a separate press release (Exhibit 99.2) regarding the director changes. No unusual items or contingencies are described in the body of this report.
Investor Verification Checklist
- Review Exhibit 99.1 for the specific financial results (revenue, EPS, margins) for the quarter ended June 30, 2026.
- Confirm the details of the new director's compensation under the standard non-employee director program referenced in the March 27, 2026 proxy statement.
- Verify the composition of the Audit and Quality and Compliance Committees following the appointment of Paul Diaz.
- Check for any subsequent filings that may incorporate the financial data from the press release into the official record.